These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20426436)

  • 21. Inhibition of CD28/CD3-mediated costimulation of naive and memory human T lymphocytes by intracellular incorporation of polyclonal antibodies specific for the activator protein-1 transcriptional complex.
    Woodside DG; McIntyre BW
    J Immunol; 1998 Jul; 161(2):649-58. PubMed ID: 9670939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes.
    Hernandez-Caselles T; Rubio G; Campanero MR; del Pozo MA; Muro M; Sanchez-Madrid F; Aparicio P
    Eur J Immunol; 1993 Nov; 23(11):2799-806. PubMed ID: 8223855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.
    Mercier-Letondal P; Montcuquet N; Sauce D; Certoux JM; Jeanningros S; Ferrand C; Bonyhadi M; Tiberghien P; Robinet E
    Cytotherapy; 2008; 10(3):275-88. PubMed ID: 18418773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes.
    van Lier RA; Brouwer M; Rebel VI; van Noesel CJ; Aarden LA
    Immunology; 1989 Sep; 68(1):45-50. PubMed ID: 2530156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4.
    Waclavicek M; Majdic O; Stulnig T; Berger M; Baumruker T; Knapp W; Pickl WF
    J Immunol; 1997 Dec; 159(11):5345-54. PubMed ID: 9548474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
    Levine BL; Bernstein WB; Connors M; Craighead N; Lindsten T; Thompson CB; June CH
    J Immunol; 1997 Dec; 159(12):5921-30. PubMed ID: 9550389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent immobilization of glucose oxidase onto poly(styrene-co-glycidyl methacrylate) monodisperse fluorescent microspheres synthesized by dispersion polymerization.
    Hou X; Liu B; Deng X; Zhang B; Chen H; Luo R
    Anal Biochem; 2007 Sep; 368(1):100-10. PubMed ID: 17562322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells.
    Costello R; Cerdan C; Pavon C; Brailly H; Hurpin C; Mawas C; Olive D
    Eur J Immunol; 1993 Mar; 23(3):608-13. PubMed ID: 8095456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
    MacMillan HF; Lee T; Issekutz AC
    Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficient CD4+ T cell proliferation in the class 1 MHC-restricted 2C TCR-transgenic mouse.
    Chen FL; Kung JT
    J Immunol; 1996 Mar; 156(6):2036-44. PubMed ID: 8690890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
    Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
    Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation.
    Walker C; Bettens F; Pichler WJ
    Eur J Immunol; 1987 Jun; 17(6):873-80. PubMed ID: 2439351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naive human T-cells become non-responsive towards anti-TNFalpha (infliximab) treatment in vitro if co-stimulated through CD28.
    Gunnlaugsdottir B; Skaftadottir I; Ludviksson BR
    Scand J Immunol; 2008 Dec; 68(6):624-34. PubMed ID: 19000096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD28 co-stimulation of T-cell-mediated cytotoxicity.
    Azuma M; Phillips JH; Lanier LL
    Int J Cancer Suppl; 1992; 7():33-5. PubMed ID: 1330948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation.
    Verwilghen J; Baroja ML; Van Vaeck F; Van Damme J; Ceuppens JL
    Immunology; 1991 Feb; 72(2):269-76. PubMed ID: 1826671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.